ArticlePLoS computational biology2026
CAPYBARA: A generalizable framework for predicting serological measurements across human cohorts.
Article in PLoS computational biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapid growth of biological datasets presents an opportunity to leverage past studies to inform and predict outcomes in new experiments. A central challenge is to distinguish which serological patterns are universally conserved and which are specific to individual datasets. In the context of human serology studies, where antibody-virus interactions assess the strength and breadth of the antibody response and inform vaccine strain selection, differences in cohort demographics or experimental design can markedly impact responses, yet few methods can translate these differences into the value±uncertainty of future measurements. Here, we introduce CAPYBARA, a data-driven framework that quantifies how serological relations map across datasets. As a case study, we applied CAPYBARA to 25 influenza datasets from 1997-2023 that measured vaccine or infection responses against multiple influenza variants using hemagglutination inhibition (HAI). To demonstrate how a subset of measurements in each study can infer the remaining data, we withheld all HAI measurements for each variant and accurately predicted them with a 2.0-fold mean absolute error-on par with experimental assay variability. Although studies with similar designs showed the best predictive power (e.g., children data are better predicted by children than adult data), predictions across age groups, between vaccination and infection studies, and across studies conducted <10 years apart showed comparable 2‒3-fold accuracy. By analyzing feature importance in this interpretable model, we identified global cross-reactivity trends that can be directly applied in future longitudinal or vaccine studies to infer broad serological responses from a small subset of measurements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.